Gilead Sciences (NASDAQ:GILD) Releases FY 2025 Earnings Guidance

Key Points

• Gilead Sciences has updated its FY 2025 earnings guidance, projecting earnings per share between $7.950 and $8.250, slightly below the consensus estimate of $7.962.
• The company expects revenue in the range of $28.3 billion to $28.7 billion, aligning close to the consensus revenue estimate of $28.7 billion.
• Recent analyst ratings have varied, with Oppenheimer lowering its price target to $125.00, while Needham upgraded its rating to "buy" with a target price of $133.00.

Gilead Sciences (NASDAQ:GILD - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 7.950-8.250 for the period, compared to the consensus EPS estimate of 7.962. The company issued revenue guidance of $28.3 billion-$28.7 billion, compared to the consensus revenue estimate of $28.7 billion.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $0.05 during trading on Monday, hitting $119.36. 1,274,610 shares of the stock were exchanged, compared to its average volume of 8,372,614. The stock has a market capitalization of $148.11 billion, a price-to-earnings ratio of 23.80, a price-to-earnings-growth ratio of 0.75 and a beta of 0.33. The company has a fifty day moving average price of $110.93 and a 200-day moving average price of $107.64. Gilead Sciences has a 1-year low of $72.43 and a 1-year high of $121.38. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.01 EPS. As a group, equities analysts predict that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences's payout ratio is presently 62.95%.

Analysts Set New Price Targets

Several brokerages recently commented on GILD. Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday. Finally, Oppenheimer cut their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $114.82.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $8,984,175 in the last ninety days. Insiders own 0.27% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Gilead Sciences stock. Bison Wealth LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,328 shares of the biopharmaceutical company's stock, valued at approximately $215,000. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.